Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients With Previously Treated Multiple Myeloma

NCT01242930 is registered in ClinicalTrials.gov with Geron Corporation as lead sponsor.

NCT NCT01242930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01242930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients With Previously Treated Multiple Myeloma
Lead sponsor
Geron Corporation
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
November 30, 2014
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma